Key Points
- EVP Ratnakar Lavu sold 1,300 Elevance Health shares at an average of $440, totaling $572,000. He retained 14,849 shares after reducing his position by 8.05%.
- Elevance reported quarterly EPS of $6.99, beating the $4.71 consensus, while revenue of $50.44 billion also exceeded expectations and rose 0.7% year over year.
- The company declared a quarterly dividend of $1.72 per share, equivalent to $6.88 annually and a 1.6% yield. Analysts hold a consensus “Moderate Buy” rating with a $456.48 average price target.
Elevance Health, Inc. (NYSE:ELV - Get Free Report) EVP Ratnakar Lavu sold 1,300 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $440.00, for a total transaction of $572,000.00. Following the transaction, the executive vice president owned 14,849 shares of the company's stock, valued at $6,533,560. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Elevance Health Stock Down 1.4%
ELV stock opened at $426.17 on Friday. The firm's 50 day moving average price is $412.92 and its 200-day moving average price is $373.58. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.47 and a current ratio of 1.47. The firm has a market cap of $92.08 billion, a PE ratio of 18.17, a PEG ratio of 1.97 and a beta of 0.63. Elevance Health, Inc. has a one year low of $274.84 and a one year high of $450.69.
Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, topping the consensus estimate of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The business had revenue of $50.44 billion for the quarter, compared to analysts' expectations of $49.28 billion. During the same quarter in the previous year, the firm posted $6.03 earnings per share. The company's revenue was up .7% compared to the same quarter last year. On average, equities research analysts anticipate that Elevance Health, Inc. will post 29.16 EPS for the current year.
Elevance Health Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be issued a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date is Friday, December 4th. Elevance Health's dividend payout ratio (DPR) is currently 29.34%.
Key Stories Impacting Elevance Health
Here are the key news stories impacting Elevance Health this week:
- Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
- Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
- Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
- Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.
Hedge Funds Weigh In On Elevance Health
A number of institutional investors have recently modified their holdings of the company. Field & Main Bank raised its stake in shares of Elevance Health by 1.3% during the second quarter. Field & Main Bank now owns 1,883 shares of the company's stock worth $728,000 after acquiring an additional 25 shares in the last quarter. Simplicity Wealth LLC lifted its position in shares of Elevance Health by 1.3% in the 3rd quarter. Simplicity Wealth LLC now owns 1,939 shares of the company's stock worth $754,000 after purchasing an additional 25 shares during the period. Tranquilli Financial Advisor LLC grew its stake in Elevance Health by 1.3% during the 2nd quarter. Tranquilli Financial Advisor LLC now owns 2,081 shares of the company's stock valued at $805,000 after purchasing an additional 26 shares during the last quarter. Mather Group LLC. grew its position in Elevance Health by 3.5% during the third quarter. Mather Group LLC. now owns 766 shares of the company's stock valued at $298,000 after buying an additional 26 shares during the period. Finally, 55 North Private Wealth LLC boosted its stake in shares of Elevance Health by 4.5% in the third quarter. 55 North Private Wealth LLC now owns 598 shares of the company's stock worth $233,000 after acquiring an additional 26 shares during the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
ELV has been the topic of a number of recent research reports. Robert W. Baird upped their target price on shares of Elevance Health from $393.00 to $406.00 and gave the stock a "neutral" rating in a research report on Thursday, October 22nd. Mizuho set a $490.00 target price on shares of Elevance Health in a research note on Friday, October 23rd. Sanford C. Bernstein set a $488.00 price target on Elevance Health in a research report on Thursday, July 16th. TD Cowen raised their price objective on Elevance Health from $465.00 to $495.00 and gave the company a "buy" rating in a research note on Friday, October 23rd. Finally, UBS Group increased their target price on Elevance Health from $460.00 to $523.00 and gave the company a "buy" rating in a research note on Thursday, October 22nd. Fifteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $456.48.
Read Our Latest Stock Report on ELV
About Elevance Health
(
Get Free Report)
Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.
The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.
Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
